SCHEMBL6743963

SCHEMBL6743963

C=CCOC(Cc1ccc(CCN(CCCCCCC)C(=O)OC(C)(C)C)cc1)C(=O)OC

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.38
PPARA Q07869 5/20 0.37
PPARG P37231 4/20 0.37
PPARD Q03181 2/20 0.37
THRB P10828 6/20 0.35
THRA P10827 5/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
CA14 Q9ULX7 1/20 0.33
CTSK P43235 2/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA4 P22748 1/20 0.33
SPHK1 Q9NYA1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6744419 0.93 L3MBTL1 (0.38) L3MBTL1PPARAPPARGPPARDTHRB
SCHEMBL6744717 0.90 PPARA (0.41) PPARAPPARGPPARDHDAC3HDAC1
SCHEMBL6744678 0.88 PPARA (0.41) PPARAPPARGPPARDTHRBTHRA
SCHEMBL6750124 0.83 PPARA (0.47) L3MBTL1PPARAPPARGPPARDHDAC3
SCHEMBL6361337 0.81 PPARA (0.40) PPARAPPARGHDAC3HDAC1HDAC2
SCHEMBL6746542 0.78 HDAC3 (0.41) L3MBTL1PPARAPPARGTHRBTHRA
SCHEMBL6744038 0.77 PPARA (0.39) PPARAPPARGPPARDTHRBTHRA
SCHEMBL6745446 0.76 PPARA (0.36) PPARAPPARGHDAC3HDAC1HDAC2
SCHEMBL6743523 0.76 PPARG (0.44) PPARAPPARGPPARDTHRBTHRA
SCHEMBL6746951 0.75 PPARA (0.47) L3MBTL1PPARAPPARGPPARDHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699904-B2 PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR (PPAR) AGONISTS; ATHEROSCLEROSIS AND CARDIOVASCULAR DISORDERS; FOR EXAMPLE, 3-(4-(2-(3-(2,4-DIMETHOXY-PHENYL)-1-HEPTYL-UREIDO)-ETHYL)-PHENYL)-2-ETHOXY -PROPIONIC ACID PFIZER INC. 2004-03-02 US disclosed
EP-1360172-A1 PPAR AGONISTS Pfizer Products Inc. (US) 2003-11-12 EP disclosed
US-20020165282-A1 Peroxisome proliferator activator receptor (PPAR) agonists; atherosclerosis and cardiovascular disorders; for example, 3-(4-(2-(3-(2,4-dimethoxy-phenyl)-1-heptyl-ureido)-ethyl)-phenyl)-2-ethoxy -propionic acid HAYWARD CHERYL M (US) 2002-11-07 US disclosed
WO-2002064549-A1 PPAR AGONISTS PFIZER PRODUCTS INC. (US) 2002-08-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165282-A1 Peroxisome proliferator activator receptor (PPAR) agonists; atherosclerosis and cardiovascular disorders; for example, 3-(4-(2-(3-(2,4-dimethoxy-phenyl)-1-heptyl-ureido)-ethyl)-phenyl)-2-ethoxy -propionic acid PPARA, PPARG, PPARD L3MBTL1 3591/4885PPARA 1/4885PPARG 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.